PAMLICO BIOPHARMA
Pamlico BioPharma, Inc. develops fully-human monoclonal antibodies (hmAb) for the rapid diagnosis and treatment of infectious diseases and cancer. Pamlico’s lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and from Emory University, and is anticipated to enter clinical trials in late 2015.
PAMLICO BIOPHARMA
Industry:
Biopharma Biotechnology Clinical Trials Health Care
Founded:
2011-01-01
Address:
Oklahoma City, Oklahoma, United States
Country:
United States
Website Url:
http://www.pamlicobio.com
Total Employee:
1+
Status:
Closed
Contact:
(405) 319-8165
Email Addresses:
[email protected]
Total Funding:
2.2 M USD
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Oklahoma Seed Capital Fund
Oklahoma Seed Capital Fund investment in Series A - Pamlico Biopharma
Accele Venture Partners
Accele Venture Partners investment in Series A - Pamlico Biopharma
